Drugs / HSP-130
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02629289 | Aug 2015 → Jun 2016 | neutropenia | Pfizer | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02650193 | Dec 2015 → Oct 2017 | breast cancer | Pfizer | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HSP-130 | “HSP-130” NCT02650193 ↗ |
| Route | Subcutaneous | “HSP-130, 6 mg, single subcutaneous (SC) injection in the deltoid region” NCT02629289 ↗ |